Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022382977> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2022382977 endingPage "479" @default.
- W2022382977 startingPage "479" @default.
- W2022382977 abstract "In 1973, we reported initial results of 4-drug chemotherapy, namely dactinomycin, adriamycin, cyclophosphamide and vincristine (T–2) in children with Ewing's Sarcoma(ES). Twenty previously untreated children with primary ES and 8 with metastatic disease were treated with surgery or radiation therapy(RT)(6000–7000 rads) and T-2 chemotherapy. Of the 20 children with primary ES, 15 have no evidence of disease for from 25+-76+ months (median 41+ months)from the start of treatment. The actuarial disease-free 5 year survival rate for this group of patients is 75%. Of the 8 patients presenting with metastatic disease, all had a complete response to T-2, but 7/8 had tumor recurrence. Examination of the T-2 treatment failures revealed that all relapses occurred at the end of the second year of T-2 or after therapy was stopped. In addition, of 23 patients receiving “curative” RT to their primary, 5 had local recurrences(22%) and 6(26%) had severe functional debility secondary to combined RT and T-2 chemotherapy. The conclusions drawn from this experience have led us to consider a new approach to the treatment of ES, including more aggressive initial chemotherapy and the use of surgery alone or in combination with moderate doses of RT in those patients in whom we can predict a high frequency of local recurrence or of “functional failures”. Supported by NCI Grant#CA-08748." @default.
- W2022382977 created "2016-06-24" @default.
- W2022382977 creator A5018186627 @default.
- W2022382977 creator A5022613511 @default.
- W2022382977 creator A5036307166 @default.
- W2022382977 creator A5080802246 @default.
- W2022382977 creator A5085763982 @default.
- W2022382977 date "1977-04-01" @default.
- W2022382977 modified "2023-09-27" @default.
- W2022382977 title "PRIMARY EWING'S SARCOMA: 75% DISEASE-FREE 5 YEAR SURVIVAL WITH T-2 CHEMOTHERAPY – CONSIDERATIONS FOR FUTURE THERAPEUTIC TRIALS" @default.
- W2022382977 doi "https://doi.org/10.1203/00006450-197704000-00656" @default.
- W2022382977 hasPublicationYear "1977" @default.
- W2022382977 type Work @default.
- W2022382977 sameAs 2022382977 @default.
- W2022382977 citedByCount "1" @default.
- W2022382977 crossrefType "journal-article" @default.
- W2022382977 hasAuthorship W2022382977A5018186627 @default.
- W2022382977 hasAuthorship W2022382977A5022613511 @default.
- W2022382977 hasAuthorship W2022382977A5036307166 @default.
- W2022382977 hasAuthorship W2022382977A5080802246 @default.
- W2022382977 hasAuthorship W2022382977A5085763982 @default.
- W2022382977 hasBestOaLocation W20223829771 @default.
- W2022382977 hasConcept C118487528 @default.
- W2022382977 hasConcept C126322002 @default.
- W2022382977 hasConcept C141071460 @default.
- W2022382977 hasConcept C142724271 @default.
- W2022382977 hasConcept C143998085 @default.
- W2022382977 hasConcept C2776694085 @default.
- W2022382977 hasConcept C2776755627 @default.
- W2022382977 hasConcept C2777586341 @default.
- W2022382977 hasConcept C2778256501 @default.
- W2022382977 hasConcept C2778356210 @default.
- W2022382977 hasConcept C2779134260 @default.
- W2022382977 hasConcept C2779429289 @default.
- W2022382977 hasConcept C509974204 @default.
- W2022382977 hasConcept C71924100 @default.
- W2022382977 hasConceptScore W2022382977C118487528 @default.
- W2022382977 hasConceptScore W2022382977C126322002 @default.
- W2022382977 hasConceptScore W2022382977C141071460 @default.
- W2022382977 hasConceptScore W2022382977C142724271 @default.
- W2022382977 hasConceptScore W2022382977C143998085 @default.
- W2022382977 hasConceptScore W2022382977C2776694085 @default.
- W2022382977 hasConceptScore W2022382977C2776755627 @default.
- W2022382977 hasConceptScore W2022382977C2777586341 @default.
- W2022382977 hasConceptScore W2022382977C2778256501 @default.
- W2022382977 hasConceptScore W2022382977C2778356210 @default.
- W2022382977 hasConceptScore W2022382977C2779134260 @default.
- W2022382977 hasConceptScore W2022382977C2779429289 @default.
- W2022382977 hasConceptScore W2022382977C509974204 @default.
- W2022382977 hasConceptScore W2022382977C71924100 @default.
- W2022382977 hasIssue "4" @default.
- W2022382977 hasLocation W20223829771 @default.
- W2022382977 hasOpenAccess W2022382977 @default.
- W2022382977 hasPrimaryLocation W20223829771 @default.
- W2022382977 hasRelatedWork W1952212414 @default.
- W2022382977 hasRelatedWork W1973224953 @default.
- W2022382977 hasRelatedWork W2019694656 @default.
- W2022382977 hasRelatedWork W2022382977 @default.
- W2022382977 hasRelatedWork W2036082666 @default.
- W2022382977 hasRelatedWork W2052170730 @default.
- W2022382977 hasRelatedWork W2059330875 @default.
- W2022382977 hasRelatedWork W2230522317 @default.
- W2022382977 hasRelatedWork W2411587104 @default.
- W2022382977 hasRelatedWork W2415511625 @default.
- W2022382977 hasVolume "11" @default.
- W2022382977 isParatext "false" @default.
- W2022382977 isRetracted "false" @default.
- W2022382977 magId "2022382977" @default.
- W2022382977 workType "article" @default.